RNA interference: reading the worm experiment and target suppression
Explain sequence-specific interference by double-stranded RNA in the 1998 worm study. Distinguish the small-RNA pathway and RNA-versus-protein readouts without treating these findings as evidence of a specific siRNA treatment.
Publication & corrections: infostoa · Editorial standards
Individual author and specialist reviewer information is not provided for this article.
1. The double-stranded RNA effect in worms
RNA interference (RNAi) is a eukaryotic gene-regulatory pathway in which small RNAs derived from double-stranded RNA reduce expression of complementary targets. In 1998, Fire, Mello, and colleagues reported sequence-specific gene interference by long double-stranded RNA in Caenorhabditis elegans. That experiment established the phenomenon in the worm; it did not demonstrate every biological role of RNAi or a universal antiviral function.
2. Target recognition by Dicer and Argonaute
In many eukaryotes, Dicer-family enzymes process double-stranded RNA into small fragments, and silencing complexes containing Argonaute use them to recognize targets. Whether the target is cleaved or repressed depends on sequence complementarity and biological context. Long RNA does not invariably produce siRNAs of one fixed length or a single uniform RISC pathway.
3. What should be compared in a suppression result?
Fire, Mello and colleagues injected RNA into adult worms and reported stronger, specific interference from double-stranded mixtures than from individual strands. First identify the organism, material and delivery method. An injection result does not determine delivery efficiency in another organism.
When reading an expression-suppression experiment, list target RNA abundance, protein abundance and the observed phenotype separately. These are different measurements. If only one declines, do not report that the others fell by the same proportion. Recording the comparison group, observation time and target sequence helps separate sequence recognition from the desired outcome. This is a proposed reading workflow, not a claim that the original paper measured every item.
Hannon’s 2002 review surveys biological functions and experimental uses of RNAi. These sources alone do not establish the delivery route, dose, safety or clinical benefit of a particular therapeutic siRNA.